MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

(R)-Equol

CAS No. : 221054-79-1

產(chǎn)品活性：(R)-Equol is an agonist of both ERα and ERβ with K_is of 27.4 and 15.4 nM, respectively.

研究領(lǐng)域：Vitamin D Related/Nuclear Receptor

作用靶點(diǎn)：Estrogen Receptor/ERR

In Vitro: (R)-Equol is an agonist of both ERα and ERβ with K_is of 27.4 and 15.4 nM, respectively. (R)-Equol induces a dose-dependent inhibitory effect on the invasive capacity of MDA-MB-231 cells that is significant at the highest concentration tested (50 μM). Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035).

In Vivo: Animals fed (R)-Equol have a significantly reduced number of palpable tumors over time when compare with Controls (P=0.002). Furthermore, the number of palpable tumors formed per rat in the (R)-Equol-fed group is significantly lower than that of rats treated with S-(-)equol (P=0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animal is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compare with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003).

相關(guān)產(chǎn)品：Bioactive Compound Library Plus  |  Anti-Cancer Compound Library  |  Nuclear Receptor Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Estradiol hemihydrate  |  OP-1074  |  GSK-4716  |  LSD1/ER-IN-1  |  Avobenzone  |  Cholesterol-¹³C₂  |  Cholesterol-¹⁸O  |  Diethylstilbestrol  |  ERB-196  |  FLTX1  |  Raloxifene hydrochloride  |  Tamoxifen  |  Estradiol-d₂-1  |  Bazedoxifene acetate  |  FSHR agonist 1  |  Estrone sulfate sodium  |  GNE-502  |  β-Estradiol 17-acetate  |  Enclomiphene  |  AhR modulator-1  |  PAC  |  α-Zearalenol  |  SNIPER(ER)-87  |  ERRα antagonist-2  |  Estradiol-d₂  |  Cholesterol-d₇  |  (Rac)-Hexestrol-d₄  |  Cholesterol-d  |  (E)-4-Hydroxytamoxifen  |  Dihydroresveratrol

熱門(mén)產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫(kù)，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門(mén)信號(hào)通路及疾病領(lǐng)；
•   產(chǎn)品種類(lèi)涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測(cè)分析，藥物篩選等專(zhuān)業(yè)技術(shù)服務(wù)；
•   設(shè)有專(zhuān)業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證；
•   Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專(zhuān)業(yè)團(tuán)隊(duì)跟蹤新的制藥及生命科學(xué)研究進(jìn)展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機(jī)構(gòu)建立了長(zhǎng)期的合作。